Premium
ACETYLATOR PHENOTYPE AND THE CLINICAL PHARMACOLOGY OF SLOW‐RELEASE PROCAINAMIDE
Author(s) -
CAMPBELL W.,
TILSTONE W.J.,
LAWSON D.H.,
MUTTON I.,
LAWRIE T.D.V.
Publication year - 1976
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1976.tb00352.x
Subject(s) - procainamide , pharmacology , drug , plasma levels , medicine , myocardial infarction , pharmacokinetics
1 Slow‐release procainamide given 8‐hourly is shown to produce plasma levels generally accepted as giving effective prophylaxis against ventricular dysrhythmias occurring after recent myocardial infarction. 2 Patients can be classified into ‘slow’ and ‘fast’ acetylators of procainamide. 3 Knowledge of acetylator status is helpful in determining the dose of procainamide necessary to attain effective steady‐state plasma levels while avoiding toxic ones. 4 Acetylator status cannot be assessed accurately using sulphadimidine when the patients are also taking procainamide.